As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio ...
We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...
Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...
Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...
The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results